TMCnet News
Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017SAN CARLOS, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast its Analyst Day on Wednesday, December 13, 2017 from 9:00 a.m. to 12:00 p.m. ET in New York, NY. The event will highlight Iovance’s lead clinical programs, LN-144 for the treatment of metastatic melanoma, LN-145 for recurrent and/or metastatic squamous cell carcinoma of the head and neck, and LN-145 for recurrent, metastatic or persistent cervical cancer. In addition, Iovance will discuss the expanding clinical pipeline, strategic collaborations and manufacturing plan for upcoming clinical trials. A live webcast of the presentation can be accessed on the investor page of Iovance Biotherapeutics’ website at http://www.iovance.com. A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation. About Iovance Biotherapeutics, Inc. Investor Relations Contact: |